A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial–mesenchymal transition

Manuel Beltran,¹ Isabel Puig,^{1,4} Cristina Peña,² José Miguel García,² Ana Belén Álvarez,¹ Raúl Peña,¹ Félix Bonilla,² and Antonio García de Herreros^{1,3,5}

¹Programa de Recerca en Càncer, Institut Municipal d'Investigació Mèdica (IMIM)-Hospital del Mar, Barcelona 08003, Spain;

²Servicio de Oncología Médica, Hospital Universitario Puerta de Hierro, Madrid 28035, Spain; ³Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona 08003, Spain

Expression of Snail1 in epithelial cells triggers an epithelial–mesenchymal transition (EMT). Here, we demonstrate that the synthesis of Zeb2, a transcriptional repressor of E-cadherin, is up-regulated after Snail1-induced EMT. Snail1 does not affect the synthesis of Zeb2 mRNA, but prevents the processing of a large intron located in its 5'-untranslated region (UTR). This intron contains an internal ribosome entry site (IRES) necessary for the expression of Zeb2. Maintenance of 5'-UTR Zeb2 intron is dependent on the expression of a natural antisense transcript (NAT) that overlaps the 5' splice site in the intron. Ectopic overexpression of this NAT in epithelial cells prevents splicing of the Zeb2 5'-UTR, increases the levels of Zeb2 protein, and consequently down-regulates E-cadherin mRNA and protein. The relevance of these results is demonstrated by the strong association between NAT presence and conservation of the 5'-UTR intron in cells that have undergone EMT or in human tumors with low E-cadherin expression. Therefore, the results presented in this article reveal the existence of a NAT capable of activating Zeb2 expression, explain the mechanism involved in this activation, and demonstrate that this NAT regulates *E-cadherin* expression.

[Keywords: Zeb2/Sip1; EMT; Snail1; NAT; IRES]

Received September 4, 2007; revised version accepted January 10, 2008.

Epithelial–mesenchymal transition (EMT) is a cellular process characterized by the loss of epithelial features and the acquisition of a mesenchymal phenotype (Thiery 2003; Huber et al. 2005). This morphological change is accompanied by the down-modulation of specific epithelial genes, such as *E-cadherin*, and the induction of mesenchymal genes. Ectopic overexpression of Snail1 in epithelial cells induces EMT concomitantly with the down-modulation of *E-cadherin* gene expression. Moreover, an essential role for the Snail1 transcriptional factor in EMT was demonstrated on the basis of its general induction in cellular conditions triggering this transition, and by the absence of EMT in the development of murine embryos null for *Snail1* (for review, see Peinado et al. 2007).

Snail1 represses *E-cadherin* transcription through its direct binding to 5'-CACCTG-3' boxes (E boxes) present

in the *E-cadherin* promoter (Batlle et al. 2000; Cano et al. 2000). Moreover, Snail1 induces the expression of the Zeb1 transcriptional factor (Guaita et al. 2002), a transcriptional repressor that also binds to E-cadherin promoter E-boxes (Grooteclaes and Frisch 2000; Eger et al. 2005). Zeb1/deltaEF1 belongs to a small family of transcriptional factors characterized by containing a homeodomain flanked by two separated Zn finger clusters (Verschuere et al. 1999). High levels of Zeb1 are detected in cells with a mesenchymal phenotype and are also observed after Snail1-induced EMT (Guaita et al. 2002). On the basis of these data, and the sustained expression of Zeb1 after Snail1 down-regulation (Guaita et al. 2002), it has been suggested that Zeb1 might work by extending the repression of E-cadherin initiated by Snail1.

Overexpression of Zeb2/Sip1, another member of the Zeb family (HUGO nomenclature *ZFH1B*), also induces E-cadherin down-regulation and EMT (Comijn et al. 2001; Vanderwalle et al. 2005). However, Zeb2 transcripts are not generally induced after EMT and do not always correlate with the mesenchymal phenotype (Guaita et al. 2002; Barberà et al. 2004). In this article, we demonstrate that the Zeb2 protein is also up-regulated in

⁴Present address: Developmental Genetics of Melanocytes, Centre National de la Recherche Scientifique, UMR 146, Institut Curie, Orsay Cedex 91405, France.

⁵Corresponding author.

E-MAIL agarcia@imim.es; FAX 34-93-316-0410.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.455708>.

An antisense transcript regulates Zeb2 expression

response to Snail1 expression. However, unlike Zeb1, the effect of Snail1 on Zeb2 expression does not depend on increased levels of this mRNA, but on its alternative processing. The consequences and mechanism of this impaired splicing are investigated in this study.

Results

To study the possible relevance of Zeb2 in the effects of Snail1, we analyzed the expression of the Zeb2 protein by Western blot using a recently available monoclonal antibody (mab). This mab does not recognize Zeb1 (data not shown). In four different cell lines, HT-29 M6, RWP-1, SW-480, and LS-174T, we detected increased levels of Zeb2 after stable expression of Snail1, though to different extents (Fig. 1A). However, as in previously published results from our group (Guaita et al. 2002), we did not observe significant differences in *Zeb2* RNA in these Snail1-stable transfectants and control cells. These analyses were performed by semiquantitative RT-PCR (data not shown) or quantitative RT-PCR (qRT-PCR) (Fig. 1C), using two oligonucleotides corresponding to the ORF (Fig. 1B). We then further investigated the reasons for this discrepancy.

An exhaustive analysis of these cell populations indicated that differences between Snail1 transfectants and control cells were detected when we carried out the RT-PCR analysis with two oligonucleotides corresponding to the 5' untranslated region (UTR) of *Zeb2* RNA. As shown in Figure 1D, expression of Snail1 induced the conservation of an additional 2.5-kb sequence in human *Zeb2* mRNA. Analysis of this sequence indicated that it corresponds to an intron situated between nucleotides +410 and +2928 (with respect to the main transcription site). An alternative splicing of the murine *Zeb2* 5'-UTR has been described previously by other investigators (Nelles et al. 2003).

We cloned a DNA fragment corresponding to the human *Zeb2* promoter and part of the 5'-UTR (Fig. 2A). This DNA fragment corresponds to the main promoter described in mouse (Nelles et al. 2003). In reporter assays, the activity of this fragment (−842/+475 from the main transcription site) was not significantly stimulated in cells transfected with Snail1; only in SW-480 cells was a detectable up-regulation observed (Fig. 2B). However, when we extended the construction in order to cover the entire 5'-UTR (−842/+2998), including the intron, the activity of the promoter increased reproducibly after Snail1 expression in the four cell lines studied (Fig. 2B). This higher activity of the construction correlated with the conservation of the intron in the exogenous RNA transcribed from the transfected promoter. As observed in Figure 2C, the intron was conserved only in exogenous mRNA in cells expressing Snail1. On the contrary, the 5'-UTR exon sequence was present at similar levels in control and Snail1-expressing genes, further indicating that the differences in Firefly Luciferase activity were not caused by altered gene transcription.

To analyze the origin of the low activity of the spliced form of the RNA, we eliminated part of the 5'-UTR form of this RNA. This construction, −842/+475 (Δ+70/+350),

Figure 1. Zeb2 protein is increased in Snail1 transfectants by a post-transcriptional mechanism. (A) Total cell extracts were prepared from HT-29 M6, SW-480, LS-174T, or RWP-1 cells, control or transfected with Snail1-HA cDNA (see the Materials and Methods). One-hundred-fifty micrograms of protein from total cell extracts were analyzed by Western blot using a mab specific to Zeb 2 protein. mRNA was isolated from the indicated cell lines and analyzed by qRT-PCR (C) or semiquantitative RT-PCR (D), with the oligonucleotides depicted in B. Oligos 3F–2R (C) corresponded to the translated sequence, 1F1R (D, bottom) flanked the intron present in the 5'-UTR, and 2F–1R (D, top), determined the conservation of the intron. The size of the DNA fragments amplified is indicated. The figure shows the result of one experiment out of three performed. In B, the ORF is depicted in black, the 5'-UTR and 3'-UTR exons are in gray, and the 5'-UTR intron is in white.

had threefold higher activity than −842/+475 (Fig. 2D), indicating that the +70/+350 sequence exerts a negative effect on the translation of the Luciferase. Deletion of this element did not significantly affect transcription, since both RNAs, with or without the +70/+350 sequence, were similarly expressed (Fig. 2E).

Figure 2. *Zeb2* 5'-UTR controls the expression of Luciferase. (A) Diagram of the constructions used in these assays. The sequence corresponding to the *Zeb2* promoter (-842/+1) is indicated in black, the 5'-UTR intron (+410/+2928) is indicated in gray, and the rest of the 5'-UTR is indicated in white. The relative position of the oligonucleotides used in this figure is indicated. (B) Firefly Luciferase activity was determined after transfecting the constructions into the indicated cells. Firefly Luciferase was standardized to the value of Renilla Luciferase. (C) RNA was obtained from RWP-1 cells transfected with -842/+2998 construction in pGL3 plasmid. Splicing of exogenous intron was determined by semiquantitative RT-PCR with oligonucleotides specific to the intron and the exon. At this number of cycles, no amplified product was detected in mock-transfected cells. (D) Control or RWP1 cells stably expressing Snail1 cDNA were transfected with the indicated constructions and Firefly Luciferase activity was determined as described. (E) In parallel, RNA was obtained from the above-mentioned transfected RWP-1 cells and levels of exogenous transcript were determined with the indicated oligonucleotides. Results from B and D show the average $\pm$ SD of three experiments performed in triplicate.

A possibility to explain the increased expression of Firefly Luciferase when containing the 5'-UTR intron is the presence in this element of an internal ribosome entry site (IRES). We checked if this was the case using two different methods. First, we analyzed the expression of the presumptive IRES by transfecting a DNA construction where transcription is controlled by the SV40 promoter and the IRES sequence is placed between *Renilla* and *Firefly Luciferase* ORFs (Fig. 3A). High ratios of Firefly to Renilla Luciferase indicate that the IRES is functional. We used a pRF plasmid without insert between both Luciferases as a control. The insertion of part of the 5'-UTR intron, the +2358/+2998 sequence, increased the expression of Firefly Luciferase >30-fold (Fig. 3B). Three other DNA fragments also corresponding to the intron (+525/+2356, +1158/+2356, and +1719/+2356) had no significant effect.

It is formally possible that the observed induction of IRES activity is due to spurious splicing of the bicistronic RNA transcript, eliminating the Renilla Luciferase. We therefore determined the levels of this transcript by qRT-PCR. As shown in Figure 3C, the presence of the

+2538/+2998 sequence in pRF did not alter the levels of *Renilla Luciferase* transcript; similar levels of Renilla RNA were detected when pRF or pRF-+2358/+2998 was transfected. Moreover, a transcript containing the *Renilla Luciferase* and the +2358/+2998 sequence was detected in cells transfected with pRF-+2358/+2998, indicating that both sequences are present in the same RNA.

We also studied the possibility that this increased expression of the reporter gene was due to cryptic promoter activity in the +2358/+2998 fragment. Therefore, the assay was repeated using a promoterless version of the pRF plasmid (pRFL). Although this assay indicated the existence of a weak promoter activity in this element, as previously reported for the murine gene (Nelles et al. 2003), the activation of Firefly Luciferase was clearly lower than that obtained with pRF plasmid, suggesting the existence of an IRES in this sequence (Fig. 3D).

To further demonstrate the existence of an IRES in this 5'-UTR, a bicistronic RNA was synthesized in vitro and transfected into RWP-1 cells stably expressing Snail1. This RNA contained the +2358/+2998 sequence placed between *Renilla* and *Firefly Luciferases* (Fig. 4A).

Figure 3. *Zeb2* 5'-UTR contains an IRES element. (A) Diagram of the bicistronic plasmids, pRF and pRF-L (promoterless), used in these assays. (B) RWP-1 cells were transfected with pRF plasmid containing the indicated inserts. Results were normalized according to Renilla Luciferase and referred to the value obtained with empty pRF vector. The figure shows the average $\pm$ SD of four experiments performed in triplicate. (C) pRF and pRF +2359/+2998 plasmids were transfected to RWP-1 cells; RNA was collected 2 d after transfection and analyzed by RT-PCR with the oligonucleotides indicated in the diagram, corresponding to *Renilla Luciferase* (top), *Renilla Luciferase* and +2359/+2998 insert (middle), or *Renilla Luciferase* and *Firefly Luciferase* (bottom). (D) RWP-1 cells were transfected with pRF-L and pRF-L +2359/+2998 plasmids and pRF containing just *Renilla Luciferase*. Expression of Renilla Luciferase was dependent on the expression of this plasmid; no activity was detected with pRF-L plasmid. Activity of Firefly Luciferase was normalized according to Renilla Luciferase and represented in respect to the value obtained with empty pRF-L plasmid. The figure shows the average $\pm$ SD of three experiments performed in triplicate.

Expression of Renilla Luciferase was greatly dependent on the capping of this RNA (Fig. 4B, top left panel). In the control RNA, without insert (Fig. 4B, top right panel), Firefly Luciferase was not significantly expressed. However, when the +2358/+2998 sequence was present in the RNA, Firefly Luciferase activity was detected, at ~20% of the expression of the Renilla one (Fig. 4B, bottom right panel), confirming that this sequence can work as an IRES. Moreover, Firefly Luciferase activity was independent of the addition of the cap to the RNA, further indicating that the ribosome is being recruited to an internal element (Fig. 4B, bottom right panel). Transfection of the transcript containing the +2358/+2998 sequence to control RWP-1 cells (Fig. 4C) produced similar results, although in this case the ratio between Firefly and Renilla Luciferase activities was lower than in RWP-1 cells expressing Snail1 (Fig. 4, cf. Firefly activity in B [bottom right panel] and C [right panel]). This result suggests that factors controlled by Snail1 are also relevant for full activity of this IRES.

A Northern analysis of the transfected transcript to RWP-1 Snail1 cells did not show the presence of partially degraded fragments that might contribute to Firefly Luciferase expression (Fig. 4D). Even though the autoradiograph was overexposed, we did not detect any RNA different than that corresponding to the RLuc-+2358/+2998-Fluc transcript, when a *Firefly Luciferase* ORF sequence was used as probe. As a control, a *Firefly Luciferase* transcript was observed when the plasmid pRF +2358/+2998 was transfected, in accordance with results shown in Figure 3D, indicating that this element also contains a weak promoter.

The existence of a natural antisense transcript (NAT) corresponding to the 5'-UTR of murine *Zeb2* has also been reported (Nelles et al. 2003). A similar NAT was detected in our human cells (Fig. 5A). Using rapid amplification of 5'-cDNA end (RACE), we determined that the start site of this NAT corresponded to nucleotide +743, referring to the main transcription start of sense mRNA (data not shown). The complete NAT extended

Figure 4. *Zeb2* 5'-UTR contains an IRES element. (A) A bicistronic RNA containing +2359/+2998 insert placed between *Renilla* and *Firefly Luciferase* was synthesized in vitro and capped as indicated in the Materials and Methods. This bicistronic RNA and a control without insert were transfected to RWP-1 cells ectopically expressing *Snail1* (B), or to control RWP-1 cells (C). Renilla and Luciferase activities were determined after 12 h and referred to the value obtained for Renilla Luciferase in the transfection of capped RNA. The figure shows the average $\pm$ SD of three experiments performed in triplicate. (D) RNA was isolated from RWP-1 *Snail1* cells transfected with the uncapped bicistronic transcripts 6 h after transfection, or from cells transfected with pRF-+2359/+2998 plasmid. Five micrograms of RNA were analyzed by Northern blot using a random prime [32 P]-labeled probe corresponding to *Firefly Luciferase* coding region. Migration of the 28S and 18S ribosomal RNAs is indicated. The arrows indicate the migration of the transcripts corresponding to RLuc-+2359/+2998-FLuc and FLuc.

from +743 to at least +63, therefore covering the 5' splice site of the *Zeb2* 5'-UTR placed at +411. Expression of this NAT was greatly stimulated by stable transfection of *Snail1* in the four different cell lines studied (Fig. 5B), suggesting a positive role for this NAT in the maintenance of the intron.

We also analyzed the elements controlling expression of the *Zeb2* NAT. A fragment of DNA corresponding to +678 to +2998 was placed in the opposite orientation in the pGL3 plasmid. In this orientation (+2998/+678), this construction, corresponding to -2255/+65 if we refer to the transcription start of the *Zeb2* NAT, showed significant activity inducing the expression of the reporter gene. This promoter activity was higher in cells expressing *Snail1* than in controls (Fig. 5C), indicating that the differences in the *Zeb2* NAT between these two cell populations are due to up-regulated transcription. Deletion of the +2358/+2998 element (-1615/-2265 from the NAT transcription start) greatly affected the activity of this promoter and prevented the stimulation observed in cells expressing *Snail1* (Fig. 5C). Therefore, the same element that we demonstrated above to present IRES activity in the *Zeb2* RNA is also relevant for NAT transcription.

We also determined whether expression of the *Zeb2* NAT was determinant for the conservation of the intron in the 5'-UTR. To verify this, we overexpressed this NAT in epithelial cell lines. As shown in Figure 6B, expression of this NAT induced the maintenance of the intron in the 5'-UTR of endogenous *Zeb2* mRNA. The effect of overexpression of the NAT on the activity of the *Firefly Luciferase* under the control of the -842/+2998 DNA fragment was also analyzed. Expression of the *Zeb2* NAT increased the activity of *Firefly Luciferase* in SW-480 and RWP-1 epithelial cells (Fig. 6C), without significantly affecting the levels of the transcript (Fig. 6D). As expected, transfection of the NAT did not up-regulate activity of the reporter gene when it was placed under the control of the -842/+475 DNA fragment, which constitutively lacks the intron (Fig. 6C). These results suggest the levels of the NAT control *Zeb2* 5'-UTR splicing in these cell lines.

To further characterize the relevance of the NAT in the splicing of the *Zeb2* 5'-UTR transcribed from the exogenous -842/+475 promoter, we used a mutant deficient for the transcription of the exogenous NAT. This mutant, -842/+2998 (Δ +1920/+2845) (Fig. 6A), induces the synthesis of lower levels of the NAT than the full-

Figure 5. Expression of a *Zeb2* NAT is up-regulated in *Snail1*-transfected cells. (A) The diagram shows the sequence of NAT and the correspondence with sequences of the *Zeb2* intron (shaded in gray) and the exon in 5'-UTR. The sequence within the intron corresponding to the IRES (+2357/2928) is shaded in dark gray. (B) RNA was purified from different cell lines stably transfected with control plasmids or *Snail1*-HA cDNA and analyzed by RT-PCR using oligonucleotides and conditions specific to *Zeb2* 5'-UTR NAT (see Materials and Methods). (C) The indicated fragments of the *Zeb2* gene were inserted in the opposite orientation in pGL3 plasmid. The promoter activity of these DNA fragments was analyzed in RWP1 control or expressing *Snail1*. Values refer to that obtained with the longest fragment in RWP-1 *Snail1* cells. The figure shows the average $\pm$ SD of three experiments performed in duplicate.

length DNA construct when transfected to RWP-1 *Snail1* cells (Fig. 6E). The levels of the NAT detected when we transfected the $-842/+2998$ ($\Delta+1920/+2845$) construction were comparable with those observed in untransfected RWP-1 *Snail1* cells (data not shown), indicating that they probably correspond to the endogenous NAT. Moreover, this experiment indicates that the NAT is efficiently produced from the exogenous $-842/+2998$ DNA construct. Compared with the wild-type DNA, deletion of the $+1920/+2845$ sequence affected the maintenance of the exogenous intron in RWP-*Snail1* cells (Fig. 6F, cf. lanes 3 and 7). As expected, processing of the exogenous intron was always detected in RWP-1 cells (Fig. 6F, lanes 1,5). The mutation did not promote per se the splicing of the *Zeb2* 5'-UTR, since ectopic transfection of the NAT was capable of causing retention of the exogenous intron from the $-842/+2998$ ($\Delta1920-2845$) con-

struct, when both were coexpressed either in RWP-1 or in RWP-1-*Snail1* cells (Fig. 6F, lanes 7,8).

Next, the *Zeb2* NAT was also stably cotransfected with pGFP into RWP-1 cells or SW-480 cells, and GFP-positive cells were isolated and analyzed. Expression of the NAT up-regulated *Zeb2* protein (Fig. 7A) without significantly modifying the levels of *Zeb2* mRNA when qRT-PCR analysis was performed with two oligonucleotides corresponding to the *Zeb2* ORF (Fig. 7B). As a consequence of the increase in *Zeb2* protein, E-cadherin protein and RNA were down-regulated. No significant changes were observed in the mRNA levels of two characteristic mesenchymal markers, Fibronectin and Lef-1, in the two cell lines (Fig. 7B), indicating that the *Zeb2* NAT represses E-cadherin but does not cause a complete EMT.

Finally, we analyzed whether the expression of the NAT and maintenance of the *Zeb2* 5'-UTR intron could be detected in other experimental conditions. As seen in Figure 8A, whereas the *Zeb2* ORF was ubiquitously expressed, sequences corresponding to the *Zeb2* 5'-UTR intron were observed in cell lines with low expression of E-cadherin, such as breast MDA-MB231 or MDA-MB435, and not in cell lines with a more epithelial phenotype and the highest levels of E-cadherin, such as BT-20 or MCF-7. Cells retaining the *Zeb2* 5'-UTR intron also presented higher levels of the NAT than cells showing E-cadherin expression. Similar results were obtained when we compared HT-29 M6 with A4 cells, a clone of HT-29 M6 constitutively transfected with an activated form of cPK-C α (Batlle et al. 1998). This cell line shows lower *E-cadherin* RNA levels and higher expression of *Snail1* with respect to the control cells, especially after treatment with PMA (Fig. 8A; Barberà et al. 2004). *Fibronectin* and other mesenchymal markers were also increased (Barberà et al. 2004). As above, a clear up-regulation of both the *Zeb2* NAT and *Zeb2* 5'-UTR intron were observed in A4 cells, whereas the levels of the *Zeb2* transcript were only slightly increased (Fig. 8A).

A more conclusive analysis was performed in a cell line, NuMG, that undergoes EMT upon treatment with TGF- β (Miettinen et al. 1994). As expected, this EMT was accompanied by down-regulation of *E-cadherin* expression and up-regulation of *Snail1* (Fig. 8A). We found no significant change in the levels of *Zeb2* transcript when the semiquantitative RT-PCR analysis was performed with two primers corresponding to the ORF. However, both the *Zeb2* 5'-UTR intron and NAT increased greatly after treatment with TGF- β (Fig. 8A).

A similar study was also carried out with a small set of human colon adenocarcinomas. The various *Zeb2* transcripts were measured by qRT-PCR and represented with respect to the value in distal normal tissue. As shown in Figure 8B, expression of the 5'-UTR intron and NAT correlated closely, with a Spearman coefficient of 0.732 ($P = 0.003$). Presence of the 5'-UTR intron and NAT inversely correlated with *E-cadherin* (*CDH1*) expression, with a Spearman coefficient close to -0.5 , but with a P -value above statistical significance (0.075) (Fig. 8B). On the

Figure 6. Expression of *Zeb2* NAT in epithelial cells prevents splicing of the 5'-UTR intron. (A) The different constructions used in this figure are shown, indicating also the relative position of the NAT. (B) Epithelial RWP-1 cells were transiently transfected with pcDNA3-*Zeb2* NAT or pcDNA3 as control. RNA was collected and analyzed by RT-PCR with oligonucleotides specific for NAT, *Zeb2* 5'-UTR intron, or *HPRT* as control. (C) RWP-1 or SW-480 cells were co-transfected with pcDNA3 NAT, pGL3 (-842/+2998), or pGL3 (-842/+475) and *Renilla Luciferase* expression plasmid. Firefly Luciferase was determined and normalized according to the value of *Renilla Luciferase*. The values correspond to the average $\pm$ SD of stimulation observed in three experiments performed in these two cell lines. (D) Levels of transcript from transfected cells from C were analyzed by RT-PCR with two oligonucleotides corresponding to 5'-UTR exon. (E,F) pGL3 (-842/+2998) plasmid, either wild type or with a deletion comprising nucleotides 1920–2845, was transfected to RWP-1 control or *Snail1*-expressing cells. (E) Levels of NAT were determined as above by RT-PCR. At this number of cycles, RWP-1 *Snail1* cells not transfected with pGL3 plasmids presented levels of NAT similar to those detected for pGL3 (-842/+2998)(Δ 1920–2845). (F) Analysis of the splicing of the 5'-UTR intron in the exogenous RNA was carried out as above by RT-PCR with two oligonucleotides flanking this intron. When indicated, pcDNA3-*Zeb2* NAT or pcDNA3 as control were co-transfected. In D and F, no amplified fragments corresponding to exon or intron sequences were detected at this number of cycles in mock-transfected cells.

other hand, we found no association between the expression of the *Zeb2* ORF and *CDH1*, or between that of the *Zeb2* ORF and the 5'-UTR intron or NAT (Fig. 8B).

Discussion

As shown in this article, expression of the *Zeb2* protein correlates with the conservation of a long 5'-UTR in its mRNA. Average 5'-UTRs in eukaryotic mRNAs contain 50–100 nucleotides (nt) (Hellen and Sarnow 2001). This size is compatible with the ribosome-scanning mechanism, where the ribosome binds to the cap structure at the 5' end and slides on the mRNA until finding the first AUG codon within an optimal context. However, the main transcription site for *Zeb2* (Nelles et al. 2003) generates a 3-kb 5'-UTR mRNA, which is unlikely to be suitable for this mechanism since its length inhibits ef-

ficient ribosome scanning (Kozak 2002). At the beginning of this research, we considered the possibility that a shorter (481-nt) 5'-UTR originated by splicing of this mRNA might be scanned by the ribosome. However, our results indicate that it is the longest, and not the shortest, 5'-UTR that associates with expression. Moreover, our results showing that deletion of 300 nt in the spliced 5'-UTR of *Zeb2* mRNA increases the expression of the reporter gene suggest that this processed 5'-UTR is still too long to allow translation. As indicated, its length, 481 nt, is far longer than average 5'-UTRs. The presence of this long 5'-UTR probably enables the formation of secondary structures, which prevents efficient ribosome scanning. Therefore, to produce the *Zeb2* protein, the translation machinery must use an alternative mechanism to scanning, such as internal ribosome entry.

Our results demonstrate the existence of an IRES in

Figure 7. Stable expression of *Zeb2* NAT in RWP1 or SW-480 cells up-regulates *Zeb2* protein and down-regulates *E-cadherin* mRNA and protein. RWP-1 or SW-480 cell populations stably expressing *Zeb2* NAT were obtained as indicated in the Materials and Methods. (A) Total protein extracts were prepared and analyzed by Western blot using antibodies specific to *Zeb2*, *E-cadherin*, or β -tubulin as loading control. (B) In parallel, RNA was purified and analyzed by qRT-PCR using oligonucleotides specific to *Zeb2* RNA (ORF), *E-cadherin* (*CDH1*), or the mesenchymal markers *fibronectin* (*FN1*) and *LEF-1*. The values are represented as fold in respect to the value obtained in a cell population selected after transfecting the empty vector. The figure shows the average $\pm$ range of two analysis performed.

Zeb2 mRNA, placed between nucleotides 2358 and 2998, a region seen by in silico analysis as highly structured. Insertion of this sequence in the bicistronic pRF plasmid increased the expression of the Firefly Luciferase to an extent that cannot be explained by the promoter activity of this fragment. More conclusively, this sequence induced the translation of Firefly Luciferase when a bicistronic *Renilla–Firefly Luciferase* mRNA was transfected into mesenchymal cells, an induction that was independent of the capping of this mRNA. Although IRES elements were first discovered and characterized in RNA genomes of picornaviruses that naturally lack 5'-terminal cap structures (Pelletier and Sonenberg 1988), they have also been identified in a number of eukaryotic cellular mRNAs (Hellen and Sarnow 2001). Many of these IRES-containing mRNAs are regulated during stress situations such as differentiation or apoptosis (Hellen and Sarnow 2001; Holcik and Sonenberg 2005). We showed that the activity of the *Zeb2* IRES is increased after the Snail1-induced conversion of epithelial cells to a mesenchymal phenotype, a condition that causes significant stress to the cell. Accordingly, Snail1 and *Zeb2* are induced by HIF in cells under hypoxic stress, promoting *E-cadherin* transcription down-regulation (Esteban et al. 2006; Krishnamachary et al. 2006; Evans et al. 2007). Therefore, *Zeb2* might belong to the class of genes regulated by an IRES sensitive to physiological stress. It is possible that this IRES-dependent translation of *Zeb2* is an alternative mechanism to maintain sufficient levels of *E-cadherin* repressors even in conditions where cap-dependent translation is affected, such as after severe stress. Consequently,

the contribution of the two members of the *Zeb* family, *Zeb1*, which presents a more standard promoter, and *Zeb2*, to *E-cadherin* repression might be different depending on the stress conditions associated with EMT.

Analysis of the *Zeb2* IRES using both RNA transfections and the pRF plasmid shows higher activity in mesenchymal than in epithelial cells, even though removal of the intron is prevented in epithelial cells (Fig. 4). Therefore, factors activated during EMT may be required for the complete activation of the IRES, as shown for other stress-dependent IRESes. A subject for further research consists of the identification of these factors and the analysis of the IRES stimulated during the acquisition of the migratory fibroblastic phenotype characteristic of EMT.

As explained in this article, the *Zeb2* IRES is maintained only in mature RNA in cells that have undergone EMT (Fig. 1). This provides an explanation for *Zeb2* protein up-regulation in these cells without changes in *Zeb2* mRNA content. Moreover, our data showing that *Zeb2* RNA undergoes alternative splicing might account for the different results obtained when *Zeb2* RNA levels were determined by RT-PCR, since the choice of a sense primer in the 5'-UTR intron or in the coding sequence gives different results. In any case, we cannot discard that this main control of *Zeb2* translation, based on the different activity of this IRES, may be accompanied by increased transcription of *Zeb2* mRNA in other cell systems. This would explain why other investigators have detected changes in *Zeb2* mRNA levels in EMTs induced in other cellular conditions when using RT-PCR and

Figure 8. Expression of *Zeb2* NAT and 5'-UTR correlates closely in cell lines and human tumors. RNA was obtained from the indicated cell lines (A), treated with TGF- β (5 ng/mL) when appropriate, or from a panel of 14 colon adenocarcinomas (B). The expression of the different transcripts was performed by semiquantitative RT-PCR (A) or qRT-PCR (B) as indicated in the Materials and Methods. B, top, shows the Spearman coefficient and the P index corresponding to the association of expression of the different transcripts; the bottom shows the results corresponding to the most significant correlations, indicating the Pearson correlation coefficient.

primers corresponding to different exons (Maeda et al. 2005; Bindels et al. 2006).

Impaired splicing of the IRES-containing intron is dependent on the presence of a NAT. Inhibition of splicing by a NAT was previously observed for the *c-erbA* gene (Munroe and Lazar 1991). Most NATs are transcribed from regions encoding UTRs (Lehner et al. 2002). In this case, the *Zeb2* NAT extends from +743 to at least +63, therefore covering the donor splice site situated at +410. Expression of the *Zeb2* NAT is induced after EMT in different cell systems. Preliminary assays indicated that the expression of this NAT is activated by transfection of a gain-of-function mutant of the NF- κ B pathway (M. Beltran and A.G. de Herreros, unpubl.), similarly to other mesenchymal genes induced after expression of Snail1 (G. Solanas, C. Agustí, M. Porta-de-la-Riva, D. Casagolda, F. Sánchez-Aguilera, F. Pons, S. Peiró, M. Escrivà, M.J. Larriba, A. Muñoz, et al., in prep.). Moreover, an analysis of the DNA elements controlling the expression of this NAT demonstrated that the sequence present between nucleotides +2377 and +2998 is necessary for the stimulation of transcription observed in cells

expressing Snail1. Therefore, the same element required for the stimulation of the transcription of the *Zeb2* NAT also works, when transcribed, as an IRES. The proteins binding to this element, both in the DNA or in the RNA, remain to be characterized, as well as whether some of these proteins may be associating with both nucleic acids. According to our results, this putative factor or factors should bind with greater affinity to these elements in cells expressing Snail1, in order to cause higher transcription of the NAT and greater activity of the IRES.

An analysis of a small group of tumor samples indicates that the presence of this NAT and maintenance of the 5'-UTR intron correlate closely. Although not totally significant, these two transcripts are associated with down-regulated *E-cadherin* levels, a relationship that was not observed when the *Zeb2* ORF was determined. In addition to the low number of tumors analyzed, other factors might account for this lack of total correlation between the expression of the NAT/5'-UTR intron (and presumably *Zeb2* protein) and the loss of *E-cadherin*; for instance, *Zeb1* might be also contributing to *E-cadherin* down-regulation. Alternatively, repression by *Zeb2*

might be also dependent on the levels of the transcriptional regulators p300 and CtBP, which modulate the inverse correlation between Zeb1 and E-cadherin (Peña et al. 2006). In any case, these analyses suggest that maintenance of the 5'-UTR intron is probably the consequence of increased transcription of the *Zeb2* NAT in human tumors and further underline the relevance of our findings.

The importance of antisense transcription has been stressed by the widespread occurrence of antisense transcripts in the human genome: Between 5% and 10% of all genes have an antisense counterpart (Yelin et al. 2003; Katayama et al. 2005). Evolution studies have ruled out that this high level of expression represents a leakage of the RNA transcription machinery (Dahary et al. 2005). Moreover, studies on individual NATs show that they regulate gene expression at different levels such as genomic imprinting (Rougeulle and Heard 2002), transcriptional interference (Prescott and Proudfoot 2002), translational regulation (Brantl 2002), alternative splicing (Hastings et al. 2000), and RNA editing (Peters et al. 2003). In most cases, these NATs are associated with decreased expression of their target genes. However, expression of the *Zeb2* NAT in cell lines increases the levels of Zeb2 protein. The control mechanism of Zeb2 protein expression by this NAT is depicted in Figure 9, which summarizes the results reported in this article, and the differences observed between epithelial and

mesenchymal cells (or cells that have undergone EMT). Moreover, since Zeb2 is a transcriptional repressor of E-cadherin, overexpression of the NAT causes down-regulation of E-cadherin, a key protein in the maintenance of the epithelial phenotype. It is noteworthy that this decrease in E-cadherin is not accompanied by a significant up-regulation of the expression of mesenchymal genes, suggesting that Zeb2, differently from Snail1, does not promote a full EMT in our cell models, but regulates only E-cadherin. It is possible that Zeb2 is playing a role similar to that suggested for Zeb1, thus extending or cooperating in the effect of Snail1 on E-cadherin expression. In any case, the results presented in this article demonstrate the existence of a NAT capable of activating Zeb2 expression, explain the mechanism involved in this activation, and demonstrate that this NAT regulates E-cadherin expression, suggesting a role for noncoding RNAs in the control of epithelial morphology.

Materials and methods

Cell culture

All cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal calf serum (Biological Industries) and the standard complements. Culture medium for NuMG cells was also supplemented with insulin (10 μ g/mL).

Figure 9. A model for the regulation of Zeb2 expression in epithelial and mesenchymal cells. (Left side, 1) In epithelial cells transcription of the main promoter of *Zeb2* gene (in black) generates an RNA composed of a 3-kb 5'-UTR (in gray) and the ORF (in white). Upon binding of the spliceosome (2), an intron corresponding to 2.5 kb is eliminated, generating a processed transcript with a 5'-UTR of 481 nt (3). (4) This 5'-UTR contains a sequence that inhibits scanning by the ribosomes and therefore prevents translation of Zeb2 protein. (Right side, 5) After completion of the EMT, transcription of *Zeb2* is accompanied by expression of a NAT depending on the activation of a different promoter placed 5' downstream. Expression of this NAT is greater than the long transcript (not shown) and prevents binding of the spliceosome to the 5' splice site (6) and, consequently, the intron present in the 5'-UTR is conserved (7). This intron contains an IRES situated close to the start of translation. Binding of the ribosomes to this IRES (8) makes the translation of Zeb2 protein possible (9).

The generation of colon HT-29 M6, SW-480, and LS-174T, or pancreatic RWP-1 cell populations transfected with Snail1 has been reported elsewhere (Batlle et al. 2000; Peiró et al. 2006; G. Solanas, C. Agustí, M. Porta-de-la-Riva, D. Casagolda, F. Sánchez-Aguilera, F. Pons, S. Peiró, M. Escrivà, M.J. Larriba, A. Muñoz, et al., in prep.). The characterization of A4 cells, a HT-29 M6 clone transfected with an activated form of cPK-C α , has been reported previously (Batlle et al. 1998). As indicated, these cells were treated with phorbol 12-myristate, 13-acetate (PMA) (50 nM, 24 h) (Sigma) in order to further stimulate cPK-C α activity and the mesenchymal phenotype. RWP-1 and SW-480 cells were also transfected with a pcDNA3-Zeb-2 NAT plasmid or pcDNA3 as control, and pEGFP, using a Lipofectamine Plus kit (Gibco) according to the manufacturer's instructions. Transfected cells were grown in medium containing 500 μ g/mL G-418 (Gibco) and were selected by a fluorescent-activated cell sorter. Human breast cancer cell lines MCF-7, BT-20, MDA-MB231, or MDA-MB435, or murine mammary cell line NuMG were obtained from our institute Cell Bank. When indicated, NuMG was treated with TGF- β (5 ng/mL) (PeproTec) for 7 d in order to promote EMT.

Plasmid construction

Sequences of *Zeb2* RNA were indicated according to the published mRNA sequence (NM014795.2) and referred to the main transcription start site. Our sequence also included the intron placed between +410/+2928 not present in the GeneBank RNA; sequence of this intron corresponded to that present in the chromosome 2 genomic contig, reference NT_022135.15|Hs2_22291, between 33982840 and 33985429.

Zeb2 promoter fragments -842/+475 and -842/+2998 were amplified using HT29-M6 genomic DNA and oligonucleotides corresponding to sequences -842/-861 (forward) and +442/+478 or +2976/+2998 (reverse). Oligonucleotides include SacI and BglII sites for facilitating the cloning of the fragment in the pGL3 basic plasmid. Deletion of the fragment +70/+370 from the -842/+475 *Zeb2* promoter was performed with oligonucleotides corresponding to +350/+370 as forward primer, and to +45/+70 as reverse primer. Deletion of fragment +1920/+2845 was carried out by digesting pGL3 *Zeb2* -842/+2998 with ApaI and XhoI, refilling with the Klenow fragment, and religating.

The DNA sequence containing the IRES element was cloned by amplifying the sequences +525/+2377, +1118/+2377, +1719/+2377, and +2356/+2998 (from the main transcription start site) using high-fidelity Pfx Platinum polymerase (Invitrogen). Oligonucleotides include EcoRI and NcoI sites for facilitating cloning of the fragment in plasmids pRF or pRFL (pRF without promoter), kindly provided by Dr. Raúl Méndez, (Centre de Regulació Genòmica, Barcelona, Spain).

A DNA fragment corresponding to the *Zeb2* NAT was amplified using HT 29-M6 genomic DNA and oligonucleotides corresponding to +89/+109 and +707/+727. The fragment was inserted in pcDNA3 in the antisense orientation. The NAT promoter was cloned using oligonucleotides corresponding to +670/+696 and +2356/2377 or +2976/+2998 with respect to the main transcription site, and cloned in a SmaI site of the PGL3 vector in antisense orientation. All constructions were verified by sequencing.

Transcript analysis in cell lines

Transcripts were analyzed by RT-PCR, using 0.5–1 μ g of total RNA. The semiquantitative analysis of the different spliced

forms of the 5'-UTR of the *Zeb2* RNA was performed with a One Step RT-PCR kit (Qiagen) and oligonucleotides corresponding to sequences +2976/+2998, +215/+235 and +2425/+2443 (see Table 1). The semiquantitative analysis of the NAT complementary to the *Zeb2* 5'-UTR was performed in two steps, using an oligonucleotide corresponding to sequence +89/+109 for reverse transcription, digesting with RNase, and adding another oligonucleotide corresponding to +707/+727 for PCR. Other oligonucleotides used for the analysis of the various transcripts are shown in Table 1. The levels of *Zeb2* RNA sequences in murine NMuMG cells were determined with oligonucleotides 4F-4R, 5F-5R, and 6F-6R, since they present high homology with the corresponding murine sequences; the identity of the amplified fragments was verified by sequencing.

Expression levels of transcripts were also calculated by real-time RT-PCR using SYBR Green (Roche Diagnostics). RNA levels were determined quantitatively in triplicate using the indicated primers (Table 1) on an ABI PRISM 7900HT. All quantifications were normalized to an endogenous control (*Hipoxanthine-guanine phosphoribosyl transferase*, *HPRT*). The relative quantification value for each target gene compared with the calibrator for that target is expressed as $2^{-[\text{Ct}-\text{C}_c]}$ (Ct and Cc are the mean threshold cycle differences after normalizing to *HPRT*).

Alternatively, Northern blot analysis was carried out following standard procedures. Total RNA was denatured and resolved on a 1% formaldehyde-37% agarose gel. Following transfer, the membranes were UV irradiated and prehybridized for 4 h at 55°C in Express Hybridization solution. Membranes were then hybridized in fresh hybridization solution containing a random prime [32 P]-labeled probe corresponding to the Firefly Luc ORF. Bands were visualized in a PhosphorImager.

Transcript analysis of tumor samples

Fourteen samples of colon adenocarcinomas and their matched normal colon mucosa (taken at least 3 cm from the outer tumor margin) were obtained immediately after surgery, immersed in RNA later (Ambion, Inc.), snap-frozen in liquid nitrogen, and stored at -80°C until processing. The use of these samples for the study was approved by the Research Ethics Board of the Hospital Universitario Puerta de Hierro (Madrid, Spain). RNA was extracted from tumor cells lines and from ~30 mg of tumor and normal tissues using the RNeasy Mini Kit (Qiagen). RNA samples were treated with an RNase-free DNase, DNA-free (Ambion), as in the manufacturer's protocol, and nucleic acids were quantified spectrophotometrically with a NanoDrop ND-1000 Spectrophotometer (nanoDrop Technologies, Inc.).

Four-hundred nanograms of total RNA were retro-transcribed using the Gold RNA PCR Core Kit (PE Biosystems), and RNA levels corresponding to the *Zeb2* ORF, 5'-UTR intron, *Zeb2* NAT, or *CDH1* ORF were analyzed as indicated above by qPCR using a LightCycler apparatus (Roche) and the LightCycler-Fast-Start^{PLUS} DNA Master SYBR Green I Kit (Roche). The primers used in these assays were 4F and 4R, 5F and 5R, 6F and 6R, and C2F and C2R for the *Zeb2* 5'-UTR intron, *Zeb2* ORF, *Zeb2* NAT, and *CDH1*, respectively (see Table 1). RNA levels were calculated in the normal and tumor counterpart samples in a relative quantification approach, whereby the amount of the targets was expressed in relation to the reference housekeeping gene *succinate dehydrogenase complex subunit A* (*SDHA*). The relative concentrations of the target and the reference gene were calculated by interpolation, using a standard curve of each gene plotted from the same serial dilution of cDNA from tumor tissue. The expression level of a target gene in a patient was cal-

Table 1. Sequence and characteristics of the oligonucleotides used for RT-PCR analysis

Name	Gene region	Sequence	Position	Use (RT-PCR)
1F	<i>Zeb2</i> -5'-UTR exon	5'-CCTCCCGACACTCTTGGCGA-3'	+215/+235	sq
2F	<i>Zeb2</i> -5'-UTR intron	5'-GGGCGAGTGGGCTTCCT-3'	+2425/+2443	sq
2R	<i>Zeb2</i> -5'-UTR exon translation start site	5'-CGATAAGAGCGGATCAGATGGC-3'	+2998/+2976	sq
3F	<i>Zeb2</i> -ORF	5'-GAGGCGCGCGAGAAAGG-3'	+130538/+130555	sq, q
3R	<i>Zeb2</i> -ORF	5'-GCCCAGCTTCCCGTAGCC-3'	+130778/+130760	sq, q
4F	<i>Zeb2</i> -5'-UTR intron	5'-CGTGTGCATTCCCTCCATACG-3'	+2644/+2663	q
4R	<i>Zeb2</i> -5'-UTR intron	5'-CTGTTTGGTGTGTTGCACCC-3'	+2749/+2720	q
5F	<i>Zeb2</i> -ORF	5'-TATGGCCTACACCTACCCAAC-3'	+3282/+3302	q
5R	<i>Zeb2</i> -ORF	5'-AGGCCTGACATGTAGTCTTGTG-3'	+3407/+3386	q
6F	<i>Zeb2</i> -5'-UTR exon/ <i>Zeb</i> -NAT	5'-ACAAAGATAGGTGGCGCGTG-3'	+89/+109	sq, q
6R	<i>Zeb2</i> -5'-UTR exon/ <i>Zeb</i> -NAT	5'-GCATGAAGAAGCCGCGAAGTGT-3'	+370/+350	sq, q
7F	<i>Zeb2</i> -5'-UTR exon	5'-ATAATCTATCCCAGATGCTTTCCC-3'	+2/+24	sq
FL1R	Firefly Luciferase-ORF	5'-GGCGTCTTCCATGGTGGC-3'	+12/-6	sq
RL1F	Renilla Luciferase-ORF	5'-GAATCGGATCCAGGATTCTT-3'	+788/+808	sq
RL1R	Renilla Luciferase-ORF	5'-TCTTGCGAAAAATGAAGACC-3'	+887/867	sq
S1F	<i>Snail1</i> -ORF	5'-TTCCAGCGCCCTACGACCAG-3'	+161/+181	sq
S1R	<i>Snail1</i> -ORF	5'-GCCTTTCCCACTGTCTCATC-3'	+361/+340	sq
MS1F	Murine <i>Snail1</i> ORF	5'-GCGCCCCGTCGTCCTTCTCGTC-3'	+327/+347	sq
MS1R	Murine <i>Snail1</i> ORF	5'-CTTCCGCGACTGGGGGTCCT-3'	+444/+425	sq
C1F	<i>CDH1</i> -ORF	5'-GAACGCATTGCCACATACAC-3'	+792/+812	sq, q
C1R	<i>CDH1</i> -ORF	5'-ATTCGGGCTTGTTGTCATTC-3'	+874/+894	sq, q
C2F	<i>CDH1</i> -ORF	5'-AGAACGCATTGCCACATACACTC-3'	+790//+812	q
C2R	<i>CDH1</i> -ORF	5'-CATTCTGATCGGTTACCGTGATC-3'	+893/+871	q
MC1F	Murine <i>Cdh1</i> -ORF	5'-GCGCTCCTGCTCCTGCTCCTGCTG-3'	+27/+51	sq
MC1R	Murine <i>Cdh1</i> -ORF	5'-CTGCTCCTGGCCTGTCTCCCTCTC-3'	+152/+128	sq
L1F	<i>LEF1</i> -ORF	5'-CGAAGAGGAAGGCGATTAG-3'	+787/+807	q
L1R	<i>LEF1</i> -ORF	5'-GTCTGGCCACCTCGTGTC-3'	+883/+865	q
F1F	Fibronectin-ORF	5'-AGCAAGCCCGGTTGTTATG-3'	+406/+425	q
F1R	Fibronectin-ORF	5'-GCTCCACTGTTGACCCATCTG-3'	+465/+444	q
H1F	<i>HPRT</i> -ORF	5'-GGCCAGACTTTGTTGGATTGTG-3'	+685/+701	sq, q
H1R	<i>HPRT</i> -ORF	5'-TGGCTCATCTTAGGCTTTGT-3'	+801/+785	sq, q
SDH1F	<i>SDHA</i> -ORF	5'-TGGGAACAAGAGGCGATCTG-3'	+148/+157	q
SDH1R	<i>SDHA</i> -ORF	5'-CCACCACTGCATCAAAATTCATG-3'	+223/+202	q

The oligonucleotides correspond to the sequences referred to as NM014795.2 (*Zeb2*, with the indicated intron as explained in the Materials and Methods), AY015988 (*Renilla Luciferase*), AB261988 (*Firefly Luciferase*), NM 005985.2 (*Snail1*), NM 004360.2 (*E-cadherin/CDH1*), NM 016269.2 (*LEF1*), NM 212482 (*Fibronectin*), NM 000194.1 (*HPRT*), NM004168.1 (*SDHA*), NM 009864 (murine *Cdh1*), and NM011427 (murine *Snail1*). Unless indicated, sequences correspond to the human genes. The use of these oligonucleotides for semiquantitative (sq) or quantitative (q) RT-PCR is indicated.

culated as the ratio of its expression in normal to its expression in tumor tissues (N/T).

The correlations between *Zeb2* mRNA (5'-UTR intron and ORF), NAT, and *CDH1* were studied using the Spearman and Pearson coefficient. In all statistical tests, two-tailed *P*-values ≤ 0.05 were considered statistically significant. Statistical analysis was performed using SPSS, version 11.0 (SPSS, Inc.).

In vitro transcription

Plasmids were linearized using AfeI, and transcription reactions were performed using the T/MEGAscript kit (Ambion). When indicated, RNAs were capped by adding to the reaction m7G(5')ppp(5')G Cap analog (Ambion). The integrity of the resultant RNAs was checked in 1% agarose gels.

Luciferase reporter assay

Reporter assays were performed using 200–400 ng of the indicated constructions containing the different fragments of *Zeb2* 5'-UTR sequence clones in pGL3 or pRF plasmids. Transfections were performed as reported previously using Lipofect-

amine (Gibco) (Batlle et al. 2000). When appropriate, cells were also transfected with 50 ng of the NAT inserted in the pcDNA3 plasmid. Renilla luciferase was also cotransfected to control efficiency of transfection. Expression of Firefly and Renilla luciferases was analyzed 48 h after transfection according to the manufacturer's instructions. RNA transfections were performed using 6 μ g of the bicistronic constructs synthesized in vitro, and luciferase activity was analyzed 12 h post-transfection.

Western blot

Cell extracts were prepared in SDS buffer (1% SDS, 65 mM Tris-HCl at pH 8.8), lysates were clarified by centrifugation, and supernatants were collected. Western blots were performed according to standard procedures using mabs against *Zeb2* (Abcam), *E-cadherin* (BD Biosciences), or β -tubulin (Sigma). The mab against *Zeb2* does not cross-react with *Zeb1*, on the basis of the absence of signal when extracts from *Zeb1*-transfected cells were analyzed by Western blot. The two bands occasionally detected with this mab probably correspond to post-translational modifications of *Zeb2*, as has been published previously

(Long et al. 2005), since they were also observed after transfection of *Zeb2* cDNA.

Acknowledgments

We greatly appreciate the advice and help of Drs. Juan Valcarcel, Fátima Gebauer, and Raúl Méndez. This study was supported by grants from the Ministerio de Educación y Ciencia (SAF2003-02324 and SAF2006-00339) and the Asociación Española contra el Cáncer (Catalunya contra el Cáncer) to A.G.H. Partial support from the Instituto Carlos III (RD06/0020/0040) and from the Generalitat de Catalunya (2005SGR00970) is also appreciated. M.B. is a recipient of a predoctoral fellowship from the Instituto Carlos III.

References

- Barberà, M.J., Puig, I., Domínguez, D., Julien-Grille, S., Guaita-Esteruelas, S., Peiro, S., Baulida, J., Francí, C., Dedhar, S., Larue, L., et al. 2004. Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. *Oncogene* **23**: 7345–7354.
- Batlle, E., Verdú, J., Domínguez, D., Llosas, M.M., Díaz, V., Loukiili, N., Paciucci, R., Alameda, F., and García de Herberos, A. 1998. Protein kinase C- α activity differently modulates invasion and growth of intestinal cells. *J. Biol. Chem.* **273**: 15091–15098.
- Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., and García de Herberos, A. 2000. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumor cells. *Nat. Cell Biol.* **2**: 84–89.
- Bindels, S., Mestdagt, M., Vanderwalle, C., Jacobs, N., Volders, L., Noël, A., van Roy, F., Berx, G., Foidart, J.M., and Gilles, C. 2006. Regulation of vimentin by Sip1 in human epithelial breast tumor cells. *Oncogene* **25**: 4975–4985.
- Brantl, S. 2002. Antisense-RNA regulation and RNA interference. *Biochim. Biophys. Acta* **1575**: 15–25.
- Cano, A., Pérez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., del Barrio, M.G., Portillo, F., and Nieto, M.A. 2000. The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. *Nat. Cell Biol.* **2**: 78–83.
- Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, M., Huylebroeck, D., and van Roy, F. 2001. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. *Mol. Cell* **7**: 1267–1278.
- Dahary, D., Elroy-Stein, O., and Sorek, R. 2005. Naturally occurring antisense: Transcriptional leakage or real overlap? *Genome Res.* **15**: 364–368.
- Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., and Foisner, R. 2005. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. *Oncogene* **24**: 2375–2385.
- Esteban, M.A., Tran, M.G.B., Harten, S.K., Hill, P., Castellanos, M.C., Chandra, A., Raval, R., O'Brien, T.S., and Maxwell, P. 2006. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. *Cancer Res.* **66**: 3567–3575.
- Evans, A.J., Russell, R.C., Roche, O., Burry, T.N., Fish, J.E., Chow, V.W.K., Kim, W.Y., Saravanan, A., Maynard, M., Gervais, M.L., et al. 2007. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and Snail1. *Mol. Cell. Biol.* **27**: 157–169.
- Grooteclaes, M.L. and Frisch, S.M. 2000. Evidence for a function of CtBP in epithelial gene regulation and anoikis. *Oncogene* **19**: 3823–3828.
- Guaita, S., Puig, I., Francí, C., Garrido, M., Domínguez, D., Batlle, E., Sancho, E., Dedhar, S., García de Herberos, A., and Baulida, J. 2002. Snail induction of epithelial-to-mesenchymal transition in tumor cells is accompanied by MUC-1 repression and ZEB1 expression. *J. Biol. Chem.* **277**: 39209–39216.
- Hastings, M.L., Inhe, H.A., Lazar, M.A., and Munroe, S.H. 2000. Post-transcriptional regulation of thyroid hormone receptor expression by *cis*-acting sequences and a naturally occurring antisense RNA. *J. Biol. Chem.* **275**: 11507–11513.
- Hellen, C. and Sarnow, P. 2001. Internal ribosome entry sites in eukaryotic mRNA molecules. *Genes & Dev.* **15**: 1593–1621.
- Holcik, M. and Sonenberg, N. 2005. Translational control in stress and apoptosis. *Nat. Rev. Mol. Cell Biol.* **6**: 318–327.
- Huber, M.A., Kraut, N., and Beug, H. 2005. Molecular requirements for epithelial–mesenchymal transition during tumor progression. *Curr. Opin. Cell Biol.* **17**: 1–11.
- Katayama, S., Tomaru, Y., Kasukawa, T., Waki, K., Nakanishi, M., Nakamura, M., Nishida, H., Yap, C.C., Suzuki, M., Kawai, J., et al. 2005. Antisense transcription in the mammalian transcriptome. *Science* **309**: 1564–1566.
- Kozak, M. 2002. Pushing the limits of the scanning mechanism for initiation of translation. *Gene* **299**: 1–34.
- Krishnamachary, B., Zagzag, D., Nagaswa, H., Rainey, K., Okuyama, H., Baek, J.H., and Semenza, G.L. 2006. Hypoxia-inducible factor 1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFH1A and ZFH1B. *Cancer Res.* **66**: 2725–2731.
- Lehner, B., Williams, G., Campbell, D., and Sanderson, C.M. 2002. Antisense transcripts in the human genome. *Trends Genet.* **18**: 63–65.
- Long, J., Zuo, D., and Park, M. 2005. Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates transcriptional repression of E-cadherin. *J. Biol. Chem.* **280**: 35477–35489.
- Maeda, M., Johnson, K.R., and Wheelock, M.J. 2005. Cadherin switching: Essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. *J. Cell Sci.* **118**: 873–887.
- Miettinen, P.J., Ebner, R., Lopez, A.R., and Derynck, R. 1994. TGF- β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. *J. Cell Biol.* **127**: 2021–2036.
- Munroe, S.H. and Lazar, M.A. 1991. Inhibition of c-erbA mRNA splicing by a naturally occurring antisense RNA. *J. Biol. Chem.* **266**: 22083–22086.
- Nelles, L., Van de Putte, T., van Grunsven, L., Huylebroeck, D., and Verschueren, K. 2003. Organization of the mouse *Zfh1b* gene encoding the two-handed zinc finger repressor Smad-interacting protein-1. *Genomics* **82**: 460–469.
- Peinado, H., Olmeda, D., and Cano, A. 2007. Snail, ZEB and bHLH factors in tumour progression: An alliance against the epithelial phenotype? *Nat. Rev. Cancer* **7**: 415–428.
- Pelletier, J. and Sonenberg, N. 1988. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. *Nature* **334**: 320–325.
- Peiró, S., Escrivà, M.J., Puig, I., Barberà, M.J., Dave, N., Larriba, M.J., Takkunen, M., Francí, C., Muñoz, A., Virtanen, I., et al. 2006. Snail1 transcriptional repressor binds to its own promoter and controls its expression. *Nucleic Acids Res.* **34**: 2077–2084.
- Peña, C., García, J.M., García, V., Silva, J., Domínguez, G., Rodríguez, R., Maximiano, C., García de Herberos, A., Muñoz, A., and Bonilla, F. 2006. The expression levels of the tran-

- scriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. *Int. J. Cancer* **119**: 2098–2104.
- Peters, N.T., Rohrbach, J.A., Zalewski, B.A., Byrkett, C.M., and Vaughn, J.C. 2003. RNA editing and regulation of *Drosophila* 4f-rnp expression by sas-10 antisense read through mRNA transcripts. *RNA* **9**: 698–710.
- Prescott, E.M. and Proudfoot, N.J. 2002. Transcriptional collision between convergent genes in budding genes. *Proc. Natl. Acad. Sci.* **99**: 8796–8801.
- Rougeulle, C. and Heard, E. 2002. Antisense RNA in imprinting: Spreading silence through air. *Trends Genet.* **18**: 434–437.
- Thiery, J.P. 2003. Epithelial–mesenchymal transitions in development and pathologies. *Curr. Opin. Cell Biol.* **15**: 740–746.
- Vanderwalle, C., Comijn, J., De Craene, B., Vermassen, P., Bruyneel, E., Andersen, H., Tulchinsky, E., Van Roy, F., and Berx, G. 2005. Sip1/Zeb2 induces EMT by repressing genes of different epithelial cell–cell junctions. *Nucleic Acids Res.* **33**: 6566–6578.
- Verschueren, K., Remacle, J.E., Collart, C., Kraft, H., Baker, B.S., Tylzanowski, P., Nelles, L., Wuytens, G., Su, M.T., Bodmer, R., et al. 1999. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACT sequences in candidate target genes. *J. Biol. Chem.* **274**: 20489–20498.
- Yelin, R., Dahary, D., Sorek, R., Levanon, E.Y., Goldstein, O., Shoshan, A., Diber, A., Biton, S., Tamir, Y., Khosravi, R., et al. 2003. Widespread occurrence of antisense transcription in the human genome. *Nat. Biotechnol.* **21**: 379–386.

A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial–mesenchymal transition

Manuel Beltran, Isabel Puig, Cristina Peña, et al.

Genes Dev. 2008, **22**:

Access the most recent version at doi:[10.1101/gad.455708](https://doi.org/10.1101/gad.455708)

References

This article cites 37 articles, 16 of which can be accessed free at:
<http://genesdev.cshlp.org/content/22/6/756.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).